Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

E.E.W. Cohen, D. Soulières, C. Le Tourneau, J. Dinis, L. Licitra, M.-J. Ahn, A. Soria, J.-P. Machiels, N. Mach, R. Mehra, B. Burtness, P. Zhang, J. Cheng, R.F. Swaby, K.J. Harrington, M. Acosta-Rivera, D.R. Adkins, M. Aghmesheh, M. Airoldi, E. AleknaviciusY. Al-Farhat, A.P. Algazi, S. Almokadem, A. Alyasova, J.R. Bauman, M. Benasso, A. Berrocal, V. Bray, B.A. Burtness, F. Caponigro, A. Castro, T.P. Cescon, K. Chan, A. Chaudhry, B. Chauffert, E. Cohen, T. Csoszi, J.P. De Boer, J.-P. Delord, A. Dietz, C. Dupuis, L. Digue, J. Erfan, Y. Escobar Alvarez, M. Evans, M.J. Fidler, M.D. Forster, S. Friesland, A.K. Ganti, A. Russo

Research output: Contribution to journalArticlepeer-review

Cite this